CN105412787A - 治疗产后月经不调的药物 - Google Patents
治疗产后月经不调的药物 Download PDFInfo
- Publication number
- CN105412787A CN105412787A CN201510906469.6A CN201510906469A CN105412787A CN 105412787 A CN105412787 A CN 105412787A CN 201510906469 A CN201510906469 A CN 201510906469A CN 105412787 A CN105412787 A CN 105412787A
- Authority
- CN
- China
- Prior art keywords
- weight portion
- radix
- medicine
- herba
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 title claims abstract description 102
- 229940079593 drug Drugs 0.000 title claims description 47
- 208000037093 Menstruation Disturbances Diseases 0.000 title abstract description 7
- 206010027339 Menstruation irregular Diseases 0.000 title abstract description 4
- 241000756943 Codonopsis Species 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 210000000582 semen Anatomy 0.000 claims description 41
- 239000007788 liquid Substances 0.000 claims description 35
- 208000019255 Menstrual disease Diseases 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 26
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 22
- 241000628997 Flos Species 0.000 claims description 20
- 239000009636 Huang Qi Substances 0.000 claims description 20
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 20
- 108010052008 colla corii asini Proteins 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000284 extract Substances 0.000 claims description 19
- 239000012153 distilled water Substances 0.000 claims description 16
- 238000010992 reflux Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 239000002552 dosage form Substances 0.000 claims description 8
- 238000004321 preservation Methods 0.000 claims description 8
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 7
- 239000004299 sodium benzoate Substances 0.000 claims description 7
- 235000010234 sodium benzoate Nutrition 0.000 claims description 7
- -1 tincture Substances 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 6
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 238000001914 filtration Methods 0.000 claims description 6
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 230000001954 sterilising effect Effects 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000000499 gel Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007901 soft capsule Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 239000000829 suppository Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 229940098465 tincture Drugs 0.000 claims description 3
- 238000011282 treatment Methods 0.000 abstract description 87
- 239000008280 blood Substances 0.000 abstract description 56
- 210000004369 blood Anatomy 0.000 abstract description 54
- 230000000694 effects Effects 0.000 abstract description 47
- 210000004185 liver Anatomy 0.000 abstract description 47
- 210000003734 kidney Anatomy 0.000 abstract description 40
- 210000000952 spleen Anatomy 0.000 abstract description 37
- 208000024891 symptom Diseases 0.000 abstract description 28
- 230000027758 ovulation cycle Effects 0.000 abstract description 23
- 230000036760 body temperature Effects 0.000 abstract description 19
- 230000001105 regulatory effect Effects 0.000 abstract description 12
- 230000001976 improved effect Effects 0.000 abstract description 10
- 238000011160 research Methods 0.000 abstract description 9
- 230000006870 function Effects 0.000 abstract description 7
- 239000000262 estrogen Substances 0.000 abstract description 5
- 229940011871 estrogen Drugs 0.000 abstract description 5
- 210000004291 uterus Anatomy 0.000 abstract description 5
- 238000012552 review Methods 0.000 abstract description 3
- 241000213006 Angelica dahurica Species 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 241001061264 Astragalus Species 0.000 abstract 1
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 244000236521 Bupleurum rotundifolium Species 0.000 abstract 1
- 235000015221 Bupleurum rotundifolium Nutrition 0.000 abstract 1
- 244000020518 Carthamus tinctorius Species 0.000 abstract 1
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 241000110637 Cuscuta chinensis Species 0.000 abstract 1
- 235000002722 Dioscorea batatas Nutrition 0.000 abstract 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 abstract 1
- 240000001811 Dioscorea oppositifolia Species 0.000 abstract 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 abstract 1
- 244000286838 Eclipta prostrata Species 0.000 abstract 1
- 108010010803 Gelatin Proteins 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 241000207925 Leonurus Species 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000170916 Paeonia officinalis Species 0.000 abstract 1
- 235000006484 Paeonia officinalis Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 240000001341 Reynoutria japonica Species 0.000 abstract 1
- 235000018167 Reynoutria japonica Nutrition 0.000 abstract 1
- 241000951473 Schizonepeta Species 0.000 abstract 1
- 235000006533 astragalus Nutrition 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 238000007599 discharging Methods 0.000 abstract 1
- 210000005069 ears Anatomy 0.000 abstract 1
- 229920000159 gelatin Polymers 0.000 abstract 1
- 239000008273 gelatin Substances 0.000 abstract 1
- 235000019322 gelatine Nutrition 0.000 abstract 1
- 235000011852 gelatine desserts Nutrition 0.000 abstract 1
- 230000001131 transforming effect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 description 29
- 238000003304 gavage Methods 0.000 description 28
- 230000008859 change Effects 0.000 description 20
- 208000002193 Pain Diseases 0.000 description 19
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 19
- 235000009508 confectionery Nutrition 0.000 description 16
- 238000000034 method Methods 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 15
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 15
- 208000011580 syndromic disease Diseases 0.000 description 15
- 239000003795 chemical substances by application Substances 0.000 description 13
- 230000003111 delayed effect Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 11
- 206010012735 Diarrhoea Diseases 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 230000005906 menstruation Effects 0.000 description 10
- 208000002173 dizziness Diseases 0.000 description 9
- 230000010354 integration Effects 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000005728 strengthening Methods 0.000 description 9
- 201000000736 Amenorrhea Diseases 0.000 description 8
- 206010001928 Amenorrhoea Diseases 0.000 description 8
- 231100000540 amenorrhea Toxicity 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000008901 benefit Effects 0.000 description 7
- 230000017531 blood circulation Effects 0.000 description 7
- 208000007106 menorrhagia Diseases 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 206010027514 Metrorrhagia Diseases 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 6
- 210000001015 abdomen Anatomy 0.000 description 6
- 239000003651 drinking water Substances 0.000 description 6
- 235000020188 drinking water Nutrition 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 239000009595 xiao yao wan Substances 0.000 description 6
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 5
- 206010013935 Dysmenorrhoea Diseases 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010030113 Oedema Diseases 0.000 description 5
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 5
- 208000031971 Yin Deficiency Diseases 0.000 description 5
- 206010003549 asthenia Diseases 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 206010016256 fatigue Diseases 0.000 description 5
- 230000035611 feeding Effects 0.000 description 5
- 239000003163 gonadal steroid hormone Substances 0.000 description 5
- 206010022437 insomnia Diseases 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000003014 reinforcing effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000002269 spontaneous effect Effects 0.000 description 5
- 208000004998 Abdominal Pain Diseases 0.000 description 4
- 206010000087 Abdominal pain upper Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 4
- 206010013975 Dyspnoeas Diseases 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 208000009205 Tinnitus Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 238000010171 animal model Methods 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000745 gonadal hormone Substances 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000002440 hepatic effect Effects 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 230000002175 menstrual effect Effects 0.000 description 4
- 238000004080 punching Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 231100000886 tinnitus Toxicity 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- 210000003462 vein Anatomy 0.000 description 4
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010021033 Hypomenorrhoea Diseases 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010047513 Vision blurred Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 208000019790 abdominal distention Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 206010061428 decreased appetite Diseases 0.000 description 3
- 208000001848 dysentery Diseases 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 229960005309 estradiol Drugs 0.000 description 3
- 229930182833 estradiol Natural products 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 208000035861 hematochezia Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 3
- 239000008108 microcrystalline cellulose Substances 0.000 description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- 206010063659 Aversion Diseases 0.000 description 2
- 208000002881 Colic Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 208000010228 Erectile Dysfunction Diseases 0.000 description 2
- 208000034507 Haematemesis Diseases 0.000 description 2
- 208000000616 Hemoptysis Diseases 0.000 description 2
- 229920000881 Modified starch Polymers 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 208000032023 Signs and Symptoms Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040943 Skin Ulcer Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 206010046798 Uterine leiomyoma Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 208000022531 anorexia Diseases 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 201000001881 impotence Diseases 0.000 description 2
- 208000021267 infertility disease Diseases 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 201000004792 malaria Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000009247 menarche Effects 0.000 description 2
- 230000003821 menstrual periods Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 230000036565 night sweats Effects 0.000 description 2
- 206010029410 night sweats Diseases 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 206010036596 premature ejaculation Diseases 0.000 description 2
- 208000037920 primary disease Diseases 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000011514 reflex Effects 0.000 description 2
- 201000005404 rubella Diseases 0.000 description 2
- 208000037921 secondary disease Diseases 0.000 description 2
- 208000013220 shortness of breath Diseases 0.000 description 2
- 231100000019 skin ulcer Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- 206010000077 Abdominal mass Diseases 0.000 description 1
- 206010000234 Abortion spontaneous Diseases 0.000 description 1
- 208000005641 Adenomyosis Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010008531 Chills Diseases 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 235000004692 Eucalyptus globulus Nutrition 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010052140 Eye pruritus Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 206010050819 Musculoskeletal chest pain Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 239000008118 PEG 6000 Substances 0.000 description 1
- 241000590428 Panacea Species 0.000 description 1
- 240000005373 Panax quinquefolius Species 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010061538 Pituitary tumour benign Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010062104 Renal mass Diseases 0.000 description 1
- 206010038490 Renal pain Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000009257 Visceral Prolapse Diseases 0.000 description 1
- 206010063840 Visceroptosis Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- LXIUJOQXHQOBSX-UHFFFAOYSA-N acetic acid chloroethene Chemical compound ClC=C.ClC=C.CC(O)=O LXIUJOQXHQOBSX-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960002233 benzalkonium bromide Drugs 0.000 description 1
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 231100000132 chronic toxicity testing Toxicity 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 201000003914 endometrial carcinoma Diseases 0.000 description 1
- 201000009274 endometriosis of uterus Diseases 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 208000017561 flaccidity Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000008216 herbs Nutrition 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010037528 lactotropin Proteins 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 208000013433 lightheadedness Diseases 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004705 lumbosacral region Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000010553 multiple abscesses Diseases 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 208000025661 ovarian cyst Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- 230000003119 painkilling effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 208000010916 pituitary tumor Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001047 pyretic effect Effects 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000004088 simulation Methods 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 208000000995 spontaneous abortion Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/533—Leonurus (motherwort)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/538—Schizonepeta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/63—Oleaceae (Olive family), e.g. jasmine, lilac or ash tree
- A61K36/638—Ligustrum, e.g. Chinese privet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/89—Cyperaceae (Sedge family)
- A61K36/8905—Cyperus (flatsedge)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供了一种用于治疗产后月经不调的中药组方,其原料药包括熟地黄、当归、白芍、柴胡、茯苓、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、山药、菟丝子、红花、益母草、酸枣仁、何首乌、阿胶、炙甘草。本发明滋肾疏肝健脾,以致气血生化有源,脏腑功能协调,冲任胞宫藏泄有道,药性平和,益上荣下,补肝肾养阴血而不滋腻,通过临床资料总结回顾,实验研究相结合,证实了本发明制剂具有治疗产后月经不调证的较明显的治疗效果。采用本发明提供的药物能够显著降低中医症状评分。既可调整月经周期,改善基础体温,并提高雌激素水平,降低过高的FSH水平。
Description
技术领域
本发明涉及中医药技术领域,尤其涉及一种治疗产后月经不调的药物。
背景技术
月经不调,是指妇女月经的异常,是妇科临床的多发病、常见病。以月经周期异常为主的有月经先期、月经后期、月经先后不定期、闭经。以经期异常为主的有经期延长。以经量异常为主的有月经过多、月经过少。其中月经后期和月经量少临床多并见,月经先期和月经过多多并见,亦有月经先期伴量少和月经后期伴量多。月经先期、月经过多、经期延长若不及时治疗可发展为崩漏。月经后期、月经过少可发展为闭经。而月经先后不定期若伴经量增多及经期延长可发展为崩漏,若伴经量减少及以后期为主可发展为闭经。其证有属寒、属热、属虚、属实之别。临床既要重视期、量、色、质的变化,还须结合全身症状及舌脉,审证求因,辨证论治。
随着现代社会的快节奏变化与现代女性朋友对自身健康的关注,月经不调已成为妇科临床上的一种常见病、多发病,且常伴有无排卵、不孕、高雄激素血症、肥胖及卵巢多囊改变,如未得到有效治疗,易发展为不孕、闭经、卵巢早衰甚至提前进入更年期。然而本病在临床治疗上缺乏有效的方法,西医多采用激素治疗为主,包括雌、孕激素的人工周期疗法、口服避孕药或促排卵药物。治疗时间长且不良反应大,若使用不当,还可能引发子宫内膜癌、乳腺癌、子宫肌瘤、脑血管疾病等。且停药后易复发。而中医药具有多环节、多靶点、整体调控的特点,中医对于本病有着独特的治疗效果,从月经产生的机制着手,注重整体观念,运用天然中药,综合调理,调动人体脏腑、气血、经络的生理功能,使之协调作用而恢复和建立正常月经周期。
而现代研究发现产次、人流、药流及自然流产是月经不调的高危因素。通常我们称这种类型为产后月经不调。产后月经不调与肝脾肾三脏功能密切相关,属于肾虚肝郁证。宜滋肾疏肝健脾,以致气血生化有源,脏腑功能协调,冲任胞宫藏泄有道的目的。因此我们选用熟地黄、当归、白芍、柴胡、茯苓、山药、菟丝子、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、红花、益母草、酸枣仁、何首乌、阿胶和炙甘草等药物。该方特别符合妇女的生理病理实际,可以治疗多种妇科疾病,尤为治疗产后月经不调肾虚肝郁型之妙方。此方药性平和,益上荣下,补肝肾养阴血而不滋腻,为平辛补肝肾至臻至妙之剂。
发明内容
本发明所要解决的技术问题是提供一种治疗产后月经不调的中药组方。本发明滋肾疏肝健脾,以致气血生化有源,脏腑功能协调,冲任胞宫藏泄有道,药性平和,益上荣下,补肝肾养阴血而不滋腻,通过临床资料总结回顾,实验研究相结合,证实了本发明制剂具有治疗产后月经不调证的较明显的治疗效果。采用本发明提供的药物能够显著降低中医症状评分。既可调整月经周期,改善基础体温,并提高雌激素水平,降低过高的FSH水平。
基于此,本发明提供一种治疗产后月经不调的药物,其原料药包括熟地黄、当归、白芍、柴胡、茯苓、山药、菟丝子、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、红花、益母草、酸枣仁、何首乌、阿胶和炙甘草。
其中,所述药物中各原料药的重量份分别为熟地黄10~20重量份、当归25~40重量份、白芍25~35重量份、柴胡1~5重量份、茯苓5~15重量份、山药15~20重量份、菟丝子25~35重量份、荆芥穗5~10重量份、女贞子5~15重量份、墨旱莲5~15重量份、党参20~30重量份、黄芪15~20重量份、砂仁10~20重量份、白术5~15重量份、香附10~20重量份、肉桂10~20重量份、红花5~15重量份、益母草20~30重量份、酸枣仁1520重量份、何首乌5~15重量份、阿胶5~10重量份、炙甘草5~10重量份。
其中,所述药物中各原料药的重量份分别为熟地黄15~20重量份、当归30~35重量份、白芍30~35重量份、柴胡1~5重量份、茯苓5~10重量份、山药15~20重量份、菟丝子25~30重量份、荆芥穗5~10重量份、女贞子10~15重量份、墨旱莲10~15重量份、党参25~30重量份、黄芪15~20重量份、砂仁10~15重量份、白术10~15重量份、香附10~15重量份、肉桂10~15重量份、红花5~10重量份、益母草25~30重量份、酸枣仁15~20重量份、何首乌10~15重量份、阿胶5~10重量份、炙甘草5~10重量份。
其中,所述药物中各原料药的重量份分别为熟地黄20重量份、当归30重量份、白芍30重量份、柴胡3重量份、茯苓10重量份、山药20重量份、菟丝子30重量份、荆芥穗10重量份、女贞子15重量份、墨旱莲10重量份、党参30重量份、黄芪20重量份、砂仁15重量份、白术15重量份、香附15重量份、肉桂15重量份、红花10重量份、益母草25重量份、酸枣仁20重量份、何首乌10重量份、阿胶10重量份、炙甘草10重量份。
本发明还提供了上述药物的制备方法,其包括:
第一步,将各原料药分别粉碎,混合在一起,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,将该超微细粉添加适当的辅料制备成所需要的剂型。
本发明药物的剂型为胶囊剂、片剂、散剂、颗粒剂、口服液、软胶囊、丸剂、酊剂、糖浆剂、栓剂、凝胶剂、喷雾剂或注射剂。
当该药物制备成口服液时,第三步具体为取80g第二步制备的超微细粉,加入蔗糖50g,尼泊金乙酯0.5g,苯甲酸钠0.3g,适量蒸馏水加热到30℃~40℃,搅拌使溶解完全,冷藏5h后再过滤一次,滤液继续添加蒸馏水调整体积至1000ml,搅匀,滤过,灌装,灭菌,即得口服液。
本发明还提供一种治疗产后月经不调的口服液,其原料药包括熟地黄、当归、白芍、柴胡、茯苓、山药、菟丝子、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、红花、益母草、酸枣仁、何首乌、阿胶和炙甘草。
有益的技术效果:
本发明提供的药物滋肾疏肝健脾,以致气血生化有源,脏腑功能协调,冲任胞宫藏泄有道,药性平和,益上荣下,补肝肾养阴血而不滋腻,通过临床资料总结回顾,实验研究相结合,证实了本发明制剂具有治疗产后月经不调证的较明显的治疗效果。采用本发明提供的药物能够显著降低中医症状评分。既可调整月经周期,改善基础体温,并提高雌激素水平,降低过高的FSH水平。
停药后3个月,本方的治疗组仍具有较稳定的疗效。对于降低中医症状评分以及中医证候的总疗效具有显著优势。
具体实施方式
本发明提供了一种治疗产后月经不调的药物,其原料药包括熟地黄、当归、白芍、柴胡、茯苓、山药、菟丝子、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、红花、益母草、酸枣仁、何首乌、阿胶和炙甘草。
进一步优选,所述药物仅由上述原料药制备而成。
所述药物中各原料药的重量份分别为熟地黄10~20重量份、当归25~40重量份、白芍25~35重量份、柴胡1~5重量份、茯苓5~15重量份、山药15~20重量份、菟丝子25~35重量份、荆芥穗5~10重量份、女贞子5~15重量份、墨旱莲5~15重量份、党参20~30重量份、黄芪15~20重量份、砂仁10~20重量份、白术5~15重量份、香附10~20重量份、肉桂10~20重量份、红花5~15重量份、益母草20~30重量份、酸枣仁15~20重量份、何首乌5~15重量份、阿胶5~10重量份、炙甘草5~10重量份。
进一步优选,所述药物中各原料药的重量份分别为熟地黄15~20重量份、当归30~35重量份、白芍30~35重量份、柴胡1~5重量份、茯苓5~10重量份、山药15~20重量份、菟丝子25~30重量份、荆芥穗5~10重量份、女贞子10~15重量份、墨旱莲10~15重量份、党参25~30重量份、黄芪15~20重量份、砂仁10~15重量份、白术10~15重量份、香附10~15重量份、肉桂10~15重量份、红花5~10重量份、益母草25~30重量份、酸枣仁15~20重量份、何首乌10~15重量份、阿胶5~10重量份、炙甘草5~10重量份。
最优选,所述药物中各原料药的重量份分别为熟地黄20重量份、当归30重量份、白芍30重量份、柴胡3重量份、茯苓10重量份、山药20重量份、菟丝子30重量份、荆芥穗10重量份、女贞子15重量份、墨旱莲10重量份、党参30重量份、黄芪20重量份、砂仁15重量份、白术15重量份、香附15重量份、肉桂15重量份、红花10重量份、益母草25重量份、酸枣仁20重量份、何首乌10重量份、阿胶10重量份、炙甘草10重量份。
本发明制剂是在临床有效方剂的基础上,根据现代医学研究进行筛选,结合中医组方配伍理论研究而成,方中熟地黄、何首乌、山药、菟丝子益肾精而养冲任,使肾精充盛,精血充足,肝肾健旺,经水则定期而至,为君药组;白芍、当归养血柔肝为主,少佐柴胡、荆芥疏肝解郁,从而疏肝兼顾养肝,当归专能补血,其气轻而辛,又能行血,故既能补血,又能活血,有和血之功,补中有动,行中有补,诚血中之气药,亦血中之圣药也,白芍味苦酸,性微寒,具有养血调经、柔肝止痛之功效与熟地黄相配,熟地黄入肾,壮水补阴,二药共奏肝肾并补之效,女贞子、墨旱莲、红花、益母草合用,与当归相配,补血和营,调经止痛,共奏养血补血,和血益阴,调经止痛之功,有活血而不峻不破、养血而不滞之特点;与柴胡、砂仁、香附、荆芥穗相配,疏柔相济,动静兼顾,阿胶养血以涵其肝体,配柴胡辛散以顺肝之性,共起疏肝解郁养血止痛之功效,二药合用共为臣药;加入大量益气健脾之药,如白术、茯苓、黄芪、党参、肉桂、炙甘草等药,脾统血女子以肝为先天,脾为后天之本,故以后天养先天,共奏其效,为佐药;酸枣仁养血柔肝,安神定志,对于产后月经不调患者除对证疗效外,还有缓解患者紧张焦虑情绪的作用。诸药合用,共奏滋肾疏肝健脾,生化气血,协调脏腑。
各原料药药理如下:
熟地黄:又名熟地,味甘,性微温,入肝、肾经,具有补血滋阴,益精填髓的作用,用于血虚萎黄;眩晕,心悸,失眠,月经不调,崩不止;肝肾阴亏,盗汗,足膝疼痛,腰膝酸软,耳鸣耳聋,头目昏花;遗精阳痿;不育不孕;月经不调;崩漏下血;须发早白;消渴;便秘;肾虚喘促等证。
当归:拉丁名AngelicaeSinensisRadix,味甘、辛,性温,入肝、心、脾经,具有补血活血,调经止痛,润肠通便的功效,主治心血不足之头晕目眩,倦怠乏力,心悸气短,血海空虚,冲任虚寒或淤血阻滞之月经不调,经痛,产或腹痛,及其他血瘀作痛及阴虚血少肠燥之便秘等证。
白芍:拉丁名PaeoniaeRadixAlba,味苦、酸,性凉,入肝、脾经,具有养血柔肝,缓中止痛,敛阴收汗的功效,主治胸腹胁肋疼痛,泻痢腹痛,自汗盗汗,阴虚发热,月经不调,崩漏,带下等证。
柴胡:拉丁名bupleuriradix,为伞形科植物柴胡或狭叶柴胡的干燥根:味苦,性微寒,归肝、胆经,具有疏散退热,升阳舒肝的功效,主治感冒发热、寒热往来、疟疾,肝郁气滞,胸肋胀痛,脱肛,子宫脱落,月经不调等证。
茯苓:味甘、淡,性平,入脾、肺、膀胱、心经,有渗湿利水、健脾宁心的作用,主要用于水湿停滞之水肿,小便不利;湿热蕴结之热淋,脾虚湿困之食少便溏、痰饮停滞、癫痫等证。
山药:拉丁名dioscoreaerhizoma,味甘,性平,入肺、脾、肾经,具有健脾补肺、益胃补肾、固肾益精、聪耳明目、助五脏、强筋骨、长志安神、延年益寿的功效,主治脾胃虚弱、倦怠无力、食欲不振、久泄久痢、肺气虚燥、痰喘咳嗽、肾气亏耗、腰膝酸软、下肢痿弱、消渴尿频、遗精早泄、带下白浊、皮肤赤肿、肥胖等证。
菟丝子:味甘、辛,性平,入肝、肾、脾经,有补肾益精,养肝明目的作用,主要用于肾阳不足之阳痿,遗精早泄,小便频数,头晕耳鸣;肾虚腰疼,妇人带下,胎气不固;肝肾两亏、肝血不足之双目昏花、视物不清;脾肾两虚之便溏腹痛,完谷不化等症状。
荆芥穗:味辛,性微温,入肺、肝经,具有祛风解表,宣毒透疹,理血止痉的功效,主治感冒寒热,头痛,目痒,咽痛,咳嗽,麻疹,风疹,痈疮,准将,吐血,血块血,便血,崩漏,产后中风、血晕等证。
女贞子:味甘、苦,微寒,入肝、肾经,有强肝益肾,清热明目的作用,主要用于治疗肝肾阴亏,头目失养之头昏耳鸣,阴虚内热等证。
墨旱莲:味甘、酸,性寒,归肝、肾经,起到不益肝肾,凉血止血的作用,用于肝肾阴虚所致头晕目眩、视物昏花,腰膝酸软;适宜于阴虚有热者,用于治疗胃中积热之吐血,热伤肺络之咳血等症状。
党参:味甘,性平,归肺、脾经,具有补气益脾,养血生津的功效,主治脾肺气虚或气血两虚之倦怠乏力、气短,咳嗽自汗等症状,党参长于补脾养胃,调理中焦,兼有养血的作用,其性平,健脾运而不燥;滋味阴而不湿,能够改善机体的免疫状态,提高抗病能力,促进消化吸收,提高新陈代谢,促进肠道对营养物质的吸收。
黄芪:拉丁名astragaliradix,味甘,性温,归脾、肺经,具有补益脾土,升举阳气、固表止汗,托疮生肌等功效,主治脾肺气虚所致之乏力食少便溏,心悸气短,中气下陷之脏器下垂,气不摄血之崩漏便血,久泻脱肛;表虚不固之自汗盗汗,气血不足等证。
砂仁:拉丁名AmomiFructus,味辛,性温,归脾经、胃经、肾经,具有化湿开胃,温脾止泻,理气安胎的功效,用于湿浊中阻,脘痞不饥,脾胃虚寒,呕吐泄泻,妊娠恶阻,胎动不安等证。
白术:拉丁名atractylodismacrocephalaerhizoma,味甘、苦,性温,入脾、胃经,有补脾利气,燥湿利水,固表止汗,运脾润燥的作用,主要用于脾失健运、气不化水所致之痞满腹泻,痰饮水肿;中气不足之心烦懒言,崩中漏下,久痢脱肛;脾虚气弱之奏里不固、虚汗自汗等证。
香附:味辛、甘、微苦,性平,归肝、三焦经,具有理气解郁,调经止痛的功效,主治肝郁气滞,胸、胁、脘腹胀痛,消化不良,月经不调,经闭痛经,寒疝腹痛,乳房胀痛等证。
肉桂:性大热,味辛、甘,归肾、脾、心、肝经,具有补火助阳,引火归源,散寒止痛,活血通经的功效,用于暖脾胃,除积冷,通血脉。治命门火衰,肢冷脉微,亡阳虚脱,腹痛泄泻,寒疝奔豚,腰膝冷痛,经闭症瘕,阴疽,流注,及虚阳浮越,上热下寒等证。
红花:性温,味辛,入、心、肝经,具有活血通经,祛瘀止痛的功效,用于闭经,痛经,恶露不行,症瘕痞块,跌扑损伤,疮疡肿痛等证。
益母草:拉丁名LeonuriHerba,味苦、辛,性微寒,入肝、心包经,具有活血调经,利尿消肿的功效,主治月经不调,痛经,经闭,恶露不尽,水肿尿少,急性肾炎水肿等证。
酸枣仁:味甘、酸,性平,具有滋养心肝,安神,敛汗的功效,主治虚烦不眠;惊悸怔忡;体虚自汗、盗汗等证。
何首乌:味苦、甘,涩,性微温,归肝、肾经,具有养血滋阴、润肠通便的功效,主治血虚头昏目眩;心悸;失眠;肝肾阴虚之腰膝酸软;须发早白;耳鸣;遗精;肠燥便秘;久疟体虚;风疹瘙痒;疮痈;瘰疬;痔疮等证。
阿胶:味甘、性平,入肺、肝、肾经,有补血止血,滋阴润燥的作用,可用于各种虚劳症状,尤其是血虚之面色萎黄,瘦弱乏力,头目晕眩,心悸失眠;营养不良性贫血,血小板减少性紫癜;虚损性咳血;吐血尿血便血;阴虚肺燥之咳嗽因干,痰中带血;邪热久羁、阴虚血耗、虚风内动之筋脉拘急、手足抽搐等证。
炙甘草:味甘,性平,入十二经,调和药性,祛痰止咳的作用,并能健脾和中,缓急止痛,主要用于补脾益气,清热解毒,祛痰止咳,缓急止痛,调和诸药。
本发明还提供了上述药物的制备方法,其包括:
第一步,将各原料药分别粉碎,混合在一起,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,将该超微细粉添加适当的辅料制备成所需要的剂型。
当该药物制备成口服液时,第三步具体为取80g第二步制备的超微细粉,加入蔗糖50g,尼泊金乙酯0.5g,苯甲酸钠0.3g,适量蒸馏水加热到30℃~40℃,搅拌使溶解完全,冷藏5h后再过滤一次,滤液继续添加蒸馏水调整体积至1000ml,搅匀,滤过,灌装,灭菌,即得口服液。
本发明药物的剂型为胶囊剂、片剂、散剂、颗粒剂、口服液、软胶囊、丸剂、酊剂、糖浆剂、栓剂、凝胶剂、喷雾剂或注射剂。
为使上述剂型能够实现,需在制备这些剂型时加入药学可接受的辅料,例如:填充剂、崩解剂、润滑剂、助悬剂、粘合剂、甜味剂、矫味剂、防腐剂、基质等。填充剂包括:淀粉、预胶化淀粉、乳糖、甘露醇、甲壳素、微晶纤维素、蔗糖等;崩解剂包括:淀粉、预胶化淀粉、微晶纤维素、羧甲基淀粉钠、交联聚乙烯吡咯烷酮、低取代羟丙纤维素、交联羧甲基纤维素钠等;润滑剂包括:硬脂酸镁、十二烷基硫酸钠、滑石粉、二氧化硅等;助悬剂包括:聚乙烯吡咯烷酮、微晶纤维素、蔗糖、琼脂、羟丙基甲基纤维素等;粘合剂包括,淀粉浆、聚乙烯吡咯烷酮、羟丙基甲基纤维素等;甜味剂包括:糖精钠、阿斯帕坦、蔗糖、甜蜜素、甘草次酸等;矫味剂包括:甜味剂及各种香精;防腐剂包括:尼泊金类、苯甲酸、苯甲酸钠、山梨酸及其盐类、苯扎溴铵、醋酸氯乙定、桉叶油等;基质包括:PEG6000,PEG4000,虫蜡等。
以下采用实施例来详细说明本发明的实施方式,借此对本发明如何应用技术手段来解决技术问题,并达成技术效果的实现过程能充分理解并据以实施。
实施例1口服液1
将熟地黄20g、当归30g、白芍30g、柴胡3g、茯苓10g、山药20g、菟丝子30g、荆芥穗10g、女贞子15g、墨旱莲10g、党参30g、黄芪20g、砂仁15g、白术15g、香附15g、肉桂15g、红花10g、益母草25g、酸枣仁20g、何首乌10g、阿胶10g、炙甘草10g分别粉碎,混合在一起,加入1.2kg的醇浓度为90%的乙醇,加热回流3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2倍的醇浓度为90%的乙醇,加热回流3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏,将干膏放置在超微粉碎机中粉碎1小时,粉碎,过筛,获得300目的超微细粉,取80g超微细粉,加入蔗糖50g,尼泊金乙酯0.5g,苯甲酸钠0.3g,适量蒸馏水加热到30℃~40℃,搅拌使溶解完全,冷藏5h后再过滤一次,滤液继续添加蒸馏水调整体积至1000ml,搅匀,滤过,灌装,灭菌,即得口服液1。
本发明大鼠急性毒性试验
1实验材料:
1.1实验动物
清洁级Wistar大鼠,40只,雌性,由山东中医药大学动物中心提供。
1.2动物饲养及实验环境
动物饲养于山东中医药大学动物中心,实验前置动物于室内适应环境一周,自由摄食和摄水,室温18~22℃,相对湿度65~70%,照明昼夜明暗交替。
2受试药物
2.1本发明实施例1制备的口服液1:灌胃,3次/日,配制成高浓度药液,浓缩至生药浓度为1.25g/ml,4℃保存,备用,使用时加热至36~39℃。
2.2空白对照组:蒸馏水灌胃,其余条件同本发明药物组。
3实验方法
按照随机数字表,将大鼠分为对照组和实验组(灌胃本发明实施例1制备的口服液,1.25g/ml,相当于生药量75g/kg/d)。灌胃量为20mL/kg,对照组灌胃蒸馏水20mL/kg。连续给药7天,停药观察3天。记录大鼠体重、进食、饮水情况,记录灌胃后大鼠各项反应,灌胃间期大鼠各项生理反应,以及死亡情况。
4结果与结论
通过急性毒理实验研究,观察7d大鼠灌胃后情况,灌胃给药前,各组动物体重、进食、饮水情况无统计学差异,灌胃给药后,各组大鼠体重变化、进食饮水情况,无统计学差异。行为学无明显异常,未出现死亡及其他毒性反应。
本实验组剂量(生药浓度75g/kg/d),是临床成人用药的180倍,现代药理学认为,对于药物急性毒性实验,最大耐受量相当于人临床日用剂量100倍以上而动物无死亡,无明显毒性反应情况出现时,该药是安全的。通过本急性毒性试验验证,无毒性反应,可以认定,本药品临床用药是安全的。
本发明大鼠慢性毒性试验
1实验材料:
1.1实验动物
清洁级Wistar大鼠,40只,雌性,由山东中医药大学动物中心提供。
1.2动物饲养及实验环境
动物饲养于山东中医药大学动物中心,实验前置动物于室内适应环境一周,自由摄食和摄水,室温18~22℃,相对湿度65~70%,照明昼夜明暗交替。
2受试药物
2.1本发明实施例1制备的口服液1:灌胃,2次/日,配制成高浓度药液,浓缩至生药浓度为0.75g/ml、0.5g/ml和0.25g/ml,4℃保存,备用,使用时加热至36~39℃。
2.2空白对照组:蒸馏水灌胃,其余条件同本发明药物组。
3实验方法
按照随机数字表,将大鼠分为对照组和高剂量组(灌胃本发明口服液1,0.75g/ml,相当于生药量45g/kg/d)、中剂量组(灌胃本口服液1,0.5g/ml,相当于生药量30g/kg/d)、低剂量组(灌胃口服液1,0.25g/ml,相当于生药量15g/kg/d)。灌胃量为20mL/kg,对照组灌胃蒸馏水20mL/kg。连续给药21天,停药观察7天。记录大鼠体重、进食、饮水情况,记录灌胃后大鼠各项反应,灌胃间期大鼠各项生理反应,以及死亡情况。
4结果与结论
实验中高中低剂量分别为45g/kg/d,30g/kg/d,15g/kg/d,对应成人临床日拟用量的108倍、72倍、36倍,连续给药3周后,通过与对照组比较各项检测指标,如一般状态、体重、进食量、饮水量各组间无统计学差异。通过对各组大鼠进行组织病理学对比分析,未见明显的毒性敏感指标和毒性靶器官。停药观察1周后,高、中、低剂量组大鼠各项检测指标均属正常,未见迟发性毒性反应和蓄积性毒性反应。
综合各组长期毒性试验结果,本发明实施例1制备的口服液1应用对大鼠无明显毒副作用,临床成人拟用剂量和疗程处于安全范围。因此对应临床使用4周的疗程中,也是处于安全范围内。
实施例2口服液2
将熟地黄15g、当归30g、白芍30g、柴胡1g、茯苓5g、山药15g、菟丝子25g、荆芥穗5g、女贞子10g、墨旱莲10g、党参25g、黄芪15g、砂仁10g、白术10g、香附10g、肉桂10g、红花5g、益母草25g、酸枣仁15g、何首乌10g、阿胶5g、炙甘草5g分别粉碎,混合在一起,加入900g的醇浓度为90%的乙醇,加热回流3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2倍的醇浓度为90%的乙醇,加热回流3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏,将干膏放置在超微粉碎机中粉碎1小时,粉碎,过筛,获得300目的超微细粉,取80g超微细粉,加入蔗糖50g,尼泊金乙酯0.5g,苯甲酸钠0.3g,适量蒸馏水加热到30℃~40℃,搅拌使溶解完全,冷藏5h后再过滤一次,滤液继续添加蒸馏水调整体积至1000ml,搅匀,滤过,灌装,灭菌,即得口服液2。
实施例3口服液3
将熟地黄20g、当归35g、白芍35g、柴胡5g、茯苓10g、山药20g、菟丝子30g、荆芥穗10g、女贞子15g、墨旱莲15g、党参30g、黄芪20g、砂仁15g、白术15g、香附15g、肉桂15g、红花10g、益母草30g、酸枣仁20g、何首乌15g、阿胶10g、炙甘草10g分别粉碎,混合在一起,加入1.2kg的醇浓度为90%的乙醇,加热回流3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量2倍的醇浓度为90%的乙醇,加热回流3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏,将干膏放置在超微粉碎机中粉碎1小时,粉碎,过筛,获得300目的超微细粉,取80g超微细粉,加入蔗糖50g,尼泊金乙酯0.5g,苯甲酸钠0.3g,适量蒸馏水加热到30℃~40℃,搅拌使溶解完全,冷藏5h后再过滤一次,滤液继续添加蒸馏水调整体积至1000ml,搅匀,滤过,灌装,灭菌,即得口服液3。
实施例4临床研究
1对象与方法
1.1研究对象
(一)合格受试对象的确定
1.病人来源:2011年6月一2011年11月在门诊就诊的月经后期患者。均系门诊病人。
2.诊断标准
(1)中医诊断标准
指月经周期错后7天以上,甚至错后3-5个月,连续出现2个月经周期以上者。
(2)中医辨证标准
肝郁肾虚型。
主症:经期错后,量少,乳房胀痛,腰骸酸痛,小腹胀痛,精神不振。
次症:经色黯淡或紫黯有块,神疲乏力、胸腹痞满、头晕耳鸣,畏寒肢冷、心悸、痛经、面色无华。
舌脉:舌暗淡,苔薄自,脉沉弦,两尺弱。
主症必备,次症1-2项加舌脉即可诊断。
兼有气血虚弱者,可见头晕眼花,倦怠乏力,气短,懒言少语,心悸失眠等;兼有痰湿阻滞者,可见带下量多粘腻;或胸闷呕恶纳差,口腻痰多;或见形体肥胖,舌体胖,苔白腻等;兼有虚寒者可见小腹冷痛喜按,得热痛减,畏寒肢冷,小便清长,便塘等。
3.纳入病例标准
(1)符合中医月经后期诊断和中医证候诊断者。
(2)受试年龄16岁一45岁。
(3)签有知情同意书者。
4.病例排除标准
(1)月经初潮未超出2年,处于妊娠期、哺乳期,或有更年期症状者。
(2)因生殖器官器质性病变(子宫肌瘤、子宫腺肌病、卵巢囊肿、垂体肿瘤等)引起的月经延后者。
(3)合并有心、脑、肝、肾及造血系统等系统的严重性疾病或精神病患者。
(4)用药过敏或过敏体质者。
(5)在治疗前半月内用过其他中西医药物治疗者。
(6)未按规定用药,无法判断疗效者。
1.2治疗方法和观察指标
(一)临床研究设计
采用随机对照的试验方法,将合格受试者以1∶1的比例随机分配至治疗组与对照组,每组90例。观察对象均为门诊就诊的病人,每个入组患者均严格控制可变因素。
(二)随机化方法
病例的分组采用简单随机的方法进行,即由临床研究人员利用SPSS17.0(统计分析系统)得出随机数字,保存于计算机并制成分配卡后加信封密封,信封号与卡片号相同。合格病例进入试验时,按其进入试验的先后次序来拆开号码相同的信封,按信封内卡片的规定进行相应的分组和治疗。
(三)治疗方法
对照组:治则为调肝补肾,养血调经。给予病人逍遥丸治疗。逍遥丸药物组成:柴胡、当归、白芍、白术(炒)、获菩、炙甘草、薄荷。服用方法:采用逍遥丸(庄松荣制药厂,卫署药制字第030877号),9克/次,一天三次,服用一周后复诊,三个月为一个疗程,停药后再追踪3个月。
治疗组:采用本发明实施例1制备的口服液治疗。服用方法:采用纯中药治疗方法,治则为调补肝肾,养血调经。20ml/次,一天三次,服用一周后复诊,三个月为一个疗程,停药后再追踪3个月。
试验期间不得使用其他任何有治疗作用的药物。
(四)疗程
每组患者在治疗前和治疗后均严格按照研究实施的要求详细填写观察表,共观察三个疗程。
(五)观察项目及观察方法
1.观察项目
临床症状:月经周期错后情况及月经量、色、质的变化,基础体温的变化、伴随症状的变化,舌脉的变化。不良反应:记录全身及局部不良反应。
主要症状及程度分级,参照《中药新药临床研究指导原则》中月经后期症状分级量化评分标准拟定。
2.观察方法
临床症状和体征均于治疗前和治疗后每周观察、记录1次。治疗前通过妇科检查、B超排除器质性疾病;必要时行CT、核磁共振等检查以排除垂体微腺瘤等垂体肿瘤。治疗一前后在月经期第2-5天空腹抽血查性激素FSH(促卵泡成熟素)、LH(促黄体生成素)、PRL(催乳素)、E2(雌二醇)、T(翠酮)。同时治疗前后监测基础体温(BBT)。
安全性指标:治疗前、后均行肝功能(ALT)、肾功能(BLTN)、血常规、尿常规、大便常规、心电图的检查。
3.临床疗效的判定标准
采用《中药新药临床研究指导原则》中月经后期的疗效判定标准,采用积分比法。疗效指数=((治疗前积分一治疗后积分)/治疗前积分)×100%
痊愈:治疗后的积分降低95%,月经周期以及月经的量、色、质均恢复至正常,基础体温显示双相,其余症状消失,且停药3个月经周期后未再发病或妊娠。
显效:治疗后的积分降低70%,月经周期错后7-10天,其余症状消失或减轻。
有效:治疗后的积分降低30%,月经周期错后>10天,但已明显缩短,其余症状减轻。
无效:治疗后的积分降低至治疗前积分的<30%,月经仍错后,无明显缩短,其他症状无改变者。
4.基础体温疗效评定标准
痊愈:基础体温由单相或不典型双相变为双相。
有效:基础体温由单相变为不典型双相。
无效:基础体温测定显示无明显改善。
5.临床研究记录
1全部病例均按上述设计的方案进行和观察,认真填病例报告表格。
2认真记录患者用药的情况,进行详细的记录和说明。
3病历及病例报告表格作为等原始记录不得更改,做任何更正时都不得改变原始记录,只能采用附加叙述的方式说明理由,并签署姓名和日期。
4临床研究中各种实验室数据均应详细记录。
5在正常范围的实验室数据也应记录,对显著偏高或在临床可接受范围以外的数据须加以核实,并做必要的说明。
6.不良反应、不良事件的记录和统计
治疗过程中,若出现“皮疹”、“瘙痒”、“心悸”、“恶心”、“呕吐”、“腹痛”、“腹胀”、“腹泻”等不良反应,需如实、详细一记录症状发生的时间、症状轻重程度、发生频率、持续时间和做出的相应处理等,分析其中可能原因并署名。参加临床试验的医师对试验中止的原因及与临床试验的关系要认真一记录,包括中止时的评价。对中途由患者提出退出临床试验的患者要明确记录原因,并详细一记录中止时评价的指标。包括:患者未按时来院复诊时,应电话、信件等询问理由调查其后的经过。
7.脱落病例处理
脱落病例均应妥善保存有关试验资料,既做留档,也是进行全分析系统所需。兰受试者脱落后,研究者应尽快与受试者联系,询问理由,一记录最后一次治疗时间,成所能完成的评估项目,因过敏或其它不良反应,治疗无效而推出试验病例,研究者应根据受试者的实际情况,采取相应的治疗措施。
1.3统计学处理
将全部数据录入EpiData3.01软件,据各症状项目的有无,分别赋值0.1,逐一整理输入相应的数值,建立本项目相关数据库。严格执行数据记录规范,调查表如修改需保持原有记录清晰可见,病历及病例报告表作为原始一记录,不得更改,做任何更正时不得改变原始记录,只能采用附加叙述说明理由,签名并注明日期。改正处需经研究者签名并注明日期。研究中各种实验室数据均应记录,对显著偏高或在临床可接受范围以外的数据须加以核实,并做必要的文字说明。全部病例均按要求认真填写病例报告表。研究结束后,将资料及时汇总并输入计算机,用EpiData3.01软件建立数据库,进行数据管理,用SPSS17.0软件进行统计分析,计量资料采用均值±标准差表示。
2结果
(一)一般资料
共收集合格受试者180例。治疗组和对照组各90例,均为门诊病人。
(二)两组治疗前可比胜比较
1.两组患者的年龄构成比较
两组患者年龄构成比较,差异无统计学意义。两组患者平均年龄构成比较,差异无统计学意义。
结果提示:两组患者的年龄具有可比性,对照组年龄均数为29.11±10.95,治疗组年龄均数为28.22±13.17,经t检验,p>0.05差异无统计学意义。
2.病程、两组月经初潮的年龄、两组患者治疗前症状评分总分、症状分级评分、基础体温情况比较、两组治疗前血清性激素检测情况、两组治疗前血清性激素、FSH(促卵泡成熟素)、LH(促黄体生成素)、PRL(催乳素)、E2(雌二醇)、T(架酮)检测情况等情况经检验,p>0.05,差异无统计学意义。
(三)治疗一个疗程后比较
1.两组患者治疗前后的症状评分降低幅度比较
表1两组患者治疗前后的症状评分比较
组别 | 治疗前症状评分总分 | 治疗后症状评分总分 | 降低幅度 |
对照组 | 23.01±3.24 | 19.10±5.12 | 3.91±2.011 |
治疗组 | 24.13±4.05 | 14.21±4.07* | 9.92±2.79★ |
注:经过独立样本T检验,*表示与治疗前比较P<0.05.★表示改变幅度与对照组比较P<0.05.
2.两组中医证候总疗效的比较
表2两组患者中医证候总疗效比较
注:经过等级资料的秩和检验,P<0.05。
两组中医证候总疗效比较,差异有统计学意义(等级资料的秩和检验,P<0.05)。对照组的总有效率为50%,治疗组的总有效率为86.66%。治疗组疗效优于对照组。
3.两组基础体温改善情况比较
表3两组患者基础体温改善情况比较
组别 | 痊愈 | 有效 | 无效 |
对照组 | 9(10.00%) | 27(30.00%) | 54(60.00%) |
治疗组 | 15(16.66%) | 51(56.66%) | 24(26.66%) |
注:基础体温改善标准为(痊愈:基础体温由单相或不典型双相变为双相:有效:基础体温由单相变为不典型双相;无效:基础体温无明显改善。)治疗前为双相的作为没有显著性改善看待。两组经过等级资料的秩和检验,P<0.05。对照组治疗一个疗程后,有效率为40.00%。治疗组有效率为73.33%,治疗组对于基础体温的改善情况显著优于对照组。
4.两组血清性激素改变情况比较
两组治疗前、后血清性激素、FSH(促卵泡成熟素)、LH(促黄体生成素)、PRL(泌乳素)、E2(雌二醇)、T(辜酮)检测改变情况,见表4。
表4两组血清性激素改变情况比较
注:经过独立样本T检验,*表示与治疗前比较P<0.05.★表示改变幅度与对照组比较P<0.05。
对于FSH,对照组与治疗组自身前后比较,具有显著性差异(P<0.05)。FSH在经过两种方法治疗后,显著降低。
对于E2,对照组与治疗组自身前后比较,具有显著性差异(P<0.05)。E2在经过两种方法治疗后,显著升高。
对照组与治疗组治疗后的改变幅度两两比较,FSH,E2有显著性差异(P<0.05)。LH,PRL,T没有显著性差异。
(四)治疗后停药3个月后比较
1,两组患者治疗后停药3个月的症状评分降低幅度比较
表5两组患者停药3个月的症状评分比较
组别 | 治疗前症状评分总分 | 治疗后停药3个月症状评分总分 | 降低幅度 |
对照组 | 23.01±3.24 | 18.01±3.28 | 5.00±2.59 |
治疗组 | 24.13±4.05 | 15.33±4.13* | 8.80±2.49★ |
经过独立样本T检验,*表示与治疗前比较P<0.05;★表示改变幅度与对照组比较P<0.05。
2.两组患者治疗后停药3个月的中医证候总疗效的比较
表6两组患者治疗后停药3个月的中医证候总疗效比较
组别 | 临床痊愈N(%) | 显效N(%) | 有效N(%) | 无效N(%) |
对照组 | 6(6.66%) | 9(10%) | 30(33.33%) | 45(50.00%) |
治疗组 | 24(26.66%) | 24(26.66%) | 30(33.33%) | 12(13.33%) |
两组中医证候总疗效比较,差异有统计学意义(等级资料的秩和检验,P<0.05)。对照组的总有效率为63.33%,治疗组的总有效率为90%。治疗组疗效优于对照组。
2.2.4药物的安全性检测
两组患者于治疗后进行肝肾功能、心电图、三大常规等安全性指标的检查,结果提示与治疗前没有变化,均在正常范围,说明定经汤加二至丸加减治疗月经后期安全可靠。
2.2.5不良事件观察
两组治疗疗期均未出现不良反应症状。
3结论
本研究结果显示,本发明制剂能有效治疗肾虚肝郁证患者,在改善中医证候,以及调节卵巢功能方面均显示其特色,值得推广应用。
1.本制剂治疗肝郁肾虚型月经后期具有良好的临床疗效,能显著降低中医症状评分。既可调整月经周期,改善基础体温,并提高雌激素水平,降低过高的FSH水平。
2.停药后3个月,使用本制剂的治疗组仍具有较稳定的疗效。对于降低中医症状评分以及中医证候的总疗效显著优于对照组(P<0.05)。
实施例6动物实验研究
1实验材料
1.1实验动物
小鼠40只,清洁级,雌性,体重(20±2g),鼠龄4-5周。动物饲养于清洁级动物室,恒温(18-25℃),湿度45%~55%,日光照12h,自由觅食饮水。经专业造模成肾虚肝郁性月经不调(模拟产后月经不调)。
1.2实验药品及制备:
1.2.1实验药物
本发明实施例1制备的口服液1、加味逍遥丸煎煮剂。
2实验方法
2.1实验动物分组及给药
40只小鼠编号按随机数字表法分为空白组、模型组、加味逍遥丸煎煮剂组、本发明口服液组。每组10只。给药:空白组予生理盐水灌胃;模型组予生理盐水灌胃、加味逍遥丸煎煮剂组给予逍遥丸汤中药灌胃;本发明口服液组给予本发明口服液灌胃。
给药量:根据人和鼠给药剂量换算公式计算各组给药的剂量。
①空白组:0.2ml/20g生理盐水灌胃,连续灌胃14天。
②模型组:0.2ml/20g生理盐水灌胃,连续灌胃14天。
③加味逍遥丸煎煮剂组:加味逍遥丸煎煮剂浓缩至0.66g/ml,0.2ml/20g灌胃,连续灌胃14天。
④本发明口服液组:本发明口服液浓缩至0.75g/ml,0.2ml/20g灌胃,连续灌胃14天。
2.5实验取材
实验结束,第14天。摘除小鼠眼球取血并处死。各组小鼠分别进行取材。
2.6检测指标及方法
2.6.1性激素指标测定
取小鼠血样,检测各项性激素指标。
2.7统计学分析
采用SPSS17.0统计软件,计量资料采用均值±标准差表示,组间比较采用方差分析和两样本均数比较的t检验。
3实验结果
1各组裸鼠体重变化情况比较
表7各组裸鼠体重变化情况
组别 | 体重变化 |
空白组 | 6.11±2.1 |
模型组 | 5.76±1.8 |
加味逍遥丸煎煮剂组 | 5.98±2.1 |
本发明口服液组 | 6.07±2.3 |
四组小鼠体重基本均处于缓慢增长。没有过于明显的差异。模型组较轻,实验组与对照组均与空白组接近。
2各项性激素指标测定结果如下:
表8FSH与LH的变化情况
指标 | 空白组 | 模型组 | 逍遥丸汤组 | 本发明口服液组 |
FSH | 4.78±1.32 | 3.57±1.67 | 3.46±0.74* | 3.01±0.57* |
LH | 26.66±6.89 | 23.70±5.34 | 18.20±2.48* | 9.01±1.14* |
注:*p<0.05。
根据结果显示,与对照组相比,实验组FSH显著降低。
表9PRL、E2与T的变化情况
注:*p<0.05。
根据结果显示,与对照组相比,实验组E2显著升高。
4结论
在本实验条件下,本发明的治疗效果非常明显,FSH激素水平显著降低,E2水平显著升高。证明了本发明的有效性。
总之,通过本实验验证,本发明中药可以改善性激素的分泌水平,恢复正常状态,有效解决产后月经不调问题。为临床推广本发明应用提供实验依据。
所有上述的首要实施这一知识产权,并没有设定限制其他形式的实施这种新产品和/或新方法。本领域技术人员将利用这一重要信息,上述内容修改,以实现类似的执行情况。但是,所有修改或改造基于本发明新产品属于保留的权利。
以上所述,仅是本发明的较佳实施例而已,并非是对本发明作其它形式的限制,任何熟悉本专业的技术人员可能利用上述揭示的技术内容加以变更或改型为等同变化的等效实施例。但是凡是未脱离本发明技术方案内容,依据本发明的技术实质对以上实施例所作的任何简单修改、等同变化与改型,仍属于本发明技术方案的保护范围。
Claims (8)
1.一种治疗产后月经不调的药物,其特征在于:原料药包括熟地黄、当归、白芍、柴胡、茯苓、山药、菟丝子、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、红花、益母草、酸枣仁、何首乌、阿胶和炙甘草。
2.如权利要求1所述的产后月经不调的药物,其特征在于:各原料药的重量份分别为熟地黄10~20重量份、当归25~40重量份、白芍25~35重量份、柴胡1~5重量份、茯苓5~15重量份、山药15~20重量份、菟丝子25~35重量份、荆芥穗5~10重量份、女贞子5~15重量份、墨旱莲5~15重量份、党参20~30重量份、黄芪15~20重量份、砂仁10~20重量份、白术5~15重量份、香附10~20重量份、肉桂10~20重量份、红花5~15重量份、益母草20~30重量份、酸枣仁15~20重量份、何首乌5~15重量份、阿胶5~10重量份、炙甘草5~10重量份。
3.如权利要求1或2所述的产后月经不调的药物,其特征在于:各原料药的重量份分别为熟地黄15~20重量份、当归30~35重量份、白芍30~35重量份、柴胡1~5重量份、茯苓5~10重量份、山药15~20重量份、菟丝子25~30重量份、荆芥穗5~10重量份、女贞子10~15重量份、墨旱莲10~15重量份、党参25~30重量份、黄芪15~20重量份、砂仁10~15重量份、白术10~15重量份、香附10~15重量份、肉桂10~15重量份、红花5~10重量份、益母草25~30重量份、酸枣仁15~20重量份、何首乌10~15重量份、阿胶5~10重量份、炙甘草5~10重量份。
4.如权利要求1至3所述的产后月经不调的药物,其特征在于:各原料药的重量份分别为熟地黄20重量份、当归30重量份、白芍30重量份、柴胡3重量份、茯苓10重量份、山药20重量份、菟丝子30重量份、荆芥穗10重量份、女贞子15重量份、墨旱莲10重量份、党参30重量份、黄芪20重量份、砂仁15重量份、白术15重量份、香附15重量份、肉桂15重量份、红花10重量份、益母草25重量份、酸枣仁20重量份、何首乌10重量份、阿胶10重量份、炙甘草10重量份。
5.权利要求1至4所述药物的制备方法,其特征在于,包括:
第一步,将各原料药分别粉碎,混合在一起,加入相对于混合物质量2~4倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第一提取液;过滤获得的药渣再加入相对于所述药渣质量1~2倍的醇浓度为85~95%的乙醇,加热回流1~3小时,提取,过滤获得第二提取液;将第一提取液和第二提取液合并,减压浓缩除去乙醇溶剂,干燥,获得干膏;
第二步,将第一步获得的干膏放置在超微粉碎机中粉碎1~2小时,粉碎,过筛,获得300目~400目的超微细粉;
第三步,将该超微细粉添加适当的辅料制备成所需要的剂型。
6.权利要求5所述药物的制备方法,其特征在于:所述药物剂型为胶囊剂、片剂、散剂、颗粒剂、口服液、软胶囊、丸剂、酊剂、糖浆剂、栓剂、凝胶剂、喷雾剂或注射剂。
7.权利要求5或6所述药物的制备方法,其特征在于:当该药物制备成口服液时,第三步具体为取80g第二步制备的超微细粉,加入蔗糖50g,尼泊金乙酯0.5g,苯甲酸钠0.3g,适量蒸馏水加热到30℃~40℃,搅拌使溶解完全,冷藏5h后再过滤一次,滤液继续添加蒸馏水调整体积至1000ml,搅匀,滤过,灌装,灭菌,即得口服液。
8.一种治疗产后月经不调的口服液,其特征在于:原料药包括熟地黄、当归、白芍、柴胡、茯苓、山药、菟丝子、荆芥穗、女贞子、墨旱莲、党参、黄芪、砂仁、白术、香附、肉桂、红花、益母草、酸枣仁、何首乌、阿胶和炙甘草。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510906469.6A CN105412787A (zh) | 2015-12-07 | 2015-12-07 | 治疗产后月经不调的药物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510906469.6A CN105412787A (zh) | 2015-12-07 | 2015-12-07 | 治疗产后月经不调的药物 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105412787A true CN105412787A (zh) | 2016-03-23 |
Family
ID=55491625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510906469.6A Pending CN105412787A (zh) | 2015-12-07 | 2015-12-07 | 治疗产后月经不调的药物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105412787A (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106728640A (zh) * | 2016-12-14 | 2017-05-31 | 赖新生 | 一种治疗月经不调促进怀孕的中药组合物 |
CN107041921A (zh) * | 2017-02-22 | 2017-08-15 | 广州军区广州总医院 | 一种用于治疗子宫发育不良、月经不调等症的组合物 |
CN107303371A (zh) * | 2016-04-18 | 2017-10-31 | 孙建业 | 一种用于女性产后月经调理的中药药酒配方 |
CN107715092A (zh) * | 2017-11-09 | 2018-02-23 | 陆惠红 | 一种治疗月经不调的药物 |
CN111084865A (zh) * | 2020-01-10 | 2020-05-01 | 青岛大学附属医院 | 一种用于产后康复的药物组合物及其制备方法与用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988672A (zh) * | 2012-11-21 | 2013-03-27 | 荣成市崖头美全口腔诊所 | 一种治疗月经不调的中药组合物 |
CN104274810A (zh) * | 2014-10-13 | 2015-01-14 | 徐鸿刚 | 一种治疗月经不调的中药组合物及其制备方法 |
-
2015
- 2015-12-07 CN CN201510906469.6A patent/CN105412787A/zh active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102988672A (zh) * | 2012-11-21 | 2013-03-27 | 荣成市崖头美全口腔诊所 | 一种治疗月经不调的中药组合物 |
CN104274810A (zh) * | 2014-10-13 | 2015-01-14 | 徐鸿刚 | 一种治疗月经不调的中药组合物及其制备方法 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107303371A (zh) * | 2016-04-18 | 2017-10-31 | 孙建业 | 一种用于女性产后月经调理的中药药酒配方 |
CN106728640A (zh) * | 2016-12-14 | 2017-05-31 | 赖新生 | 一种治疗月经不调促进怀孕的中药组合物 |
CN107041921A (zh) * | 2017-02-22 | 2017-08-15 | 广州军区广州总医院 | 一种用于治疗子宫发育不良、月经不调等症的组合物 |
CN107715092A (zh) * | 2017-11-09 | 2018-02-23 | 陆惠红 | 一种治疗月经不调的药物 |
CN111084865A (zh) * | 2020-01-10 | 2020-05-01 | 青岛大学附属医院 | 一种用于产后康复的药物组合物及其制备方法与用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103585378B (zh) | 一种治疗女性不孕症的中药组合物及其制备方法 | |
CN105412787A (zh) | 治疗产后月经不调的药物 | |
CN109528980A (zh) | 一种用于治疗卵巢储备功能下降疾病的中药组合物及其制药应用 | |
CN104524071A (zh) | 一种治疗原发性肾病的药物组合物及其用途 | |
CN104435519A (zh) | 一种治疗原发性痛经的药物组合物 | |
CN104523889B (zh) | 一种治疗滑胎的中药制剂及其制备方法 | |
CN105250556A (zh) | 一种用于治疗多囊卵巢综合征的中药药物 | |
CN105944020B (zh) | 一种治疗卵巢功能下降的中药 | |
CN110237161B (zh) | 用于治疗绝经综合征的药物及其制备方法和应用 | |
CN105497262A (zh) | 一种治疗肝肾阴虚型多囊卵巢综合征的药物组合物 | |
CN105214048A (zh) | 用于治疗寒凝血瘀型原发性痛经的药物 | |
CN104547396A (zh) | 一种治疗月经后期的中药组合物 | |
CN104056173A (zh) | 一种治疗孕妇妊娠期气血两亏的中药组合物 | |
CN102274472A (zh) | 一种治疗女性痛经的中药贴剂及制备 | |
CN105597020A (zh) | 一种治疗多囊卵巢综合征合并乳腺增生的药物组合物 | |
CN105727237A (zh) | 一种含艾叶的治疗闭经的药物组合物 | |
CN104436064A (zh) | 一种治疗痛经的药物组合物 | |
CN104398987A (zh) | 一种治疗寒凝血瘀型痛经的中药组合物及其制备方法 | |
CN111803607A (zh) | 一种用于治疗良性前列腺肥大合并肥胖症的药物组合物及其制备方法 | |
CN102362957A (zh) | 一种治疗深部红斑狼疮的中成药 | |
CN116135221A (zh) | 一种五子益冲方及其制剂和应用 | |
CN110840980A (zh) | 一种治疗女性不孕不育的中药组合物及其制备方法 | |
CN105833031A (zh) | 一种用于甲状腺癌术后心肾阴虚证的药物组合物 | |
CN105362671A (zh) | 一种治疗月经过少伴高胰岛素血症的药物组合物 | |
CN105943668A (zh) | 一种治疗血热伤胎型习惯性流产的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160323 |